Baidu
map

Br J Clin Pharmacol:孕妇服用抗抑郁药增加后台出生缺陷风险

2016-01-07 QQduhp 译 MedSci原创

孕妇服用抗抑郁药增加后台出生缺陷风险

1月是出生缺陷预防月,因此,医学界正在尽一切努力告知医务人员和患者采取一切措施以预防新生儿罹患出生缺陷。 

在最近的研究中,加拿大蒙特利尔大学的Anick Bérard教授指出,孕妇服用抗抑郁药物增加妊娠及后代患病风险,并将文章发表British Journal of Clinical Pharmacology。  

在研究中,Bérard教授和他的同事们将重点探究帕罗西汀(一种用于治疗抑郁症、恐慌症、社交焦虑症,强迫症、广泛性焦虑障碍和创伤后应激障碍的药物)。
 
帕罗西汀是SSRI(五羟色胺再摄取抑制剂)的一种,主要通过增加机体5-羟色胺的含量而发挥作用。 

据研究人员介绍,高达1/5的育龄女性出现轻到中度抑郁。此外,近年来,孕期女性获得的抗抑郁药处方增加。
 
2005年以前大多数人都认为帕罗西汀对孕妇而言是安全的,但有研究显示,帕罗西汀的摄入会增加胎儿心脏畸形的风险。 

然而,研究人员进一步的研究后发现,在欧洲和北美采用不同的研究方法会出现相互矛盾的结果,不过,孕妇摄入帕罗西汀后导致婴儿出生缺陷的风险增加。 

为了进行深入分析,研究人员对1966-2015年发表的综述和荟萃分析的相关研究进行了深入探究,其中有23篇研究经筛查后符合标准。

结果显示,相比没有使用帕罗西汀的孕妇,妊娠前三个月使用帕罗西汀的孕妇分娩的新生儿出现中枢神经系统问题的风险增加23%,出现心脏功能异常的风险增加28%。Bérard教授认为,需要严格评估帕罗西汀药物作用及对胎儿异常风险等进行风险评估。

她指出,正常情况下,胎儿出现畸形的风险是3%,心脏畸形的风险为1%。但是任何孕期用药都可能增加胎儿畸形的风险。此外,不服用抗抑郁药物且表现出轻中度抑郁的孕妇中,有85%的女性今后将于产后表现出抑郁症状。因此,医务人员需要采取切实有效的方法,如心理治疗或运动方案等减轻孕妇的困扰。 

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1995929, encodeId=5a5419959296c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Feb 19 02:47:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787182, encodeId=119b1e8718253, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 13 15:47:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908199, encodeId=300b1908199d8, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Dec 22 16:47:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722429, encodeId=cc601e22429b6, content=<a href='/topic/show?id=7ff5549865a' target=_blank style='color:#2F92EE;'>#抑郁药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54986, encryptionId=7ff5549865a, topicName=抑郁药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fa33270286, createdName=wetgdt, createdTime=Tue Nov 22 05:47:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788170, encodeId=95851e881703b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Mar 20 15:47:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62872, encodeId=9e0a628e248, content=值得注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62873, encodeId=759d628e381, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62874, encodeId=fafc628e4dc, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60051, encodeId=dc576005141, content=恩,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:58:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59047, encodeId=e6b45904ebc, content=两面剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sun Jan 24 18:30:00 CST 2016, time=2016-01-24, status=1, ipAttribution=)]
    2016-02-19 yb6560
  2. [GetPortalCommentsPageByObjectIdResponse(id=1995929, encodeId=5a5419959296c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Feb 19 02:47:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787182, encodeId=119b1e8718253, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 13 15:47:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908199, encodeId=300b1908199d8, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Dec 22 16:47:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722429, encodeId=cc601e22429b6, content=<a href='/topic/show?id=7ff5549865a' target=_blank style='color:#2F92EE;'>#抑郁药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54986, encryptionId=7ff5549865a, topicName=抑郁药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fa33270286, createdName=wetgdt, createdTime=Tue Nov 22 05:47:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788170, encodeId=95851e881703b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Mar 20 15:47:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62872, encodeId=9e0a628e248, content=值得注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62873, encodeId=759d628e381, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62874, encodeId=fafc628e4dc, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60051, encodeId=dc576005141, content=恩,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:58:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59047, encodeId=e6b45904ebc, content=两面剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sun Jan 24 18:30:00 CST 2016, time=2016-01-24, status=1, ipAttribution=)]
    2016-01-13 jj000001
  3. [GetPortalCommentsPageByObjectIdResponse(id=1995929, encodeId=5a5419959296c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Feb 19 02:47:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787182, encodeId=119b1e8718253, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 13 15:47:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908199, encodeId=300b1908199d8, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Dec 22 16:47:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722429, encodeId=cc601e22429b6, content=<a href='/topic/show?id=7ff5549865a' target=_blank style='color:#2F92EE;'>#抑郁药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54986, encryptionId=7ff5549865a, topicName=抑郁药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fa33270286, createdName=wetgdt, createdTime=Tue Nov 22 05:47:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788170, encodeId=95851e881703b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Mar 20 15:47:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62872, encodeId=9e0a628e248, content=值得注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62873, encodeId=759d628e381, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62874, encodeId=fafc628e4dc, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60051, encodeId=dc576005141, content=恩,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:58:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59047, encodeId=e6b45904ebc, content=两面剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sun Jan 24 18:30:00 CST 2016, time=2016-01-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1995929, encodeId=5a5419959296c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Feb 19 02:47:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787182, encodeId=119b1e8718253, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 13 15:47:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908199, encodeId=300b1908199d8, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Dec 22 16:47:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722429, encodeId=cc601e22429b6, content=<a href='/topic/show?id=7ff5549865a' target=_blank style='color:#2F92EE;'>#抑郁药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54986, encryptionId=7ff5549865a, topicName=抑郁药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fa33270286, createdName=wetgdt, createdTime=Tue Nov 22 05:47:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788170, encodeId=95851e881703b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Mar 20 15:47:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62872, encodeId=9e0a628e248, content=值得注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62873, encodeId=759d628e381, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62874, encodeId=fafc628e4dc, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60051, encodeId=dc576005141, content=恩,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:58:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59047, encodeId=e6b45904ebc, content=两面剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sun Jan 24 18:30:00 CST 2016, time=2016-01-24, status=1, ipAttribution=)]
    2016-11-22 wetgdt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1995929, encodeId=5a5419959296c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Feb 19 02:47:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787182, encodeId=119b1e8718253, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 13 15:47:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908199, encodeId=300b1908199d8, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Dec 22 16:47:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722429, encodeId=cc601e22429b6, content=<a href='/topic/show?id=7ff5549865a' target=_blank style='color:#2F92EE;'>#抑郁药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54986, encryptionId=7ff5549865a, topicName=抑郁药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fa33270286, createdName=wetgdt, createdTime=Tue Nov 22 05:47:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788170, encodeId=95851e881703b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Mar 20 15:47:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62872, encodeId=9e0a628e248, content=值得注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62873, encodeId=759d628e381, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62874, encodeId=fafc628e4dc, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60051, encodeId=dc576005141, content=恩,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:58:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59047, encodeId=e6b45904ebc, content=两面剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sun Jan 24 18:30:00 CST 2016, time=2016-01-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1995929, encodeId=5a5419959296c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Feb 19 02:47:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787182, encodeId=119b1e8718253, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 13 15:47:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908199, encodeId=300b1908199d8, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Dec 22 16:47:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722429, encodeId=cc601e22429b6, content=<a href='/topic/show?id=7ff5549865a' target=_blank style='color:#2F92EE;'>#抑郁药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54986, encryptionId=7ff5549865a, topicName=抑郁药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fa33270286, createdName=wetgdt, createdTime=Tue Nov 22 05:47:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788170, encodeId=95851e881703b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Mar 20 15:47:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62872, encodeId=9e0a628e248, content=值得注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62873, encodeId=759d628e381, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62874, encodeId=fafc628e4dc, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60051, encodeId=dc576005141, content=恩,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:58:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59047, encodeId=e6b45904ebc, content=两面剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sun Jan 24 18:30:00 CST 2016, time=2016-01-24, status=1, ipAttribution=)]
    2016-02-02 收获你的美

    值得注意

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1995929, encodeId=5a5419959296c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Feb 19 02:47:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787182, encodeId=119b1e8718253, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 13 15:47:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908199, encodeId=300b1908199d8, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Dec 22 16:47:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722429, encodeId=cc601e22429b6, content=<a href='/topic/show?id=7ff5549865a' target=_blank style='color:#2F92EE;'>#抑郁药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54986, encryptionId=7ff5549865a, topicName=抑郁药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fa33270286, createdName=wetgdt, createdTime=Tue Nov 22 05:47:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788170, encodeId=95851e881703b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Mar 20 15:47:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62872, encodeId=9e0a628e248, content=值得注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62873, encodeId=759d628e381, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62874, encodeId=fafc628e4dc, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60051, encodeId=dc576005141, content=恩,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:58:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59047, encodeId=e6b45904ebc, content=两面剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sun Jan 24 18:30:00 CST 2016, time=2016-01-24, status=1, ipAttribution=)]
    2016-02-02 收获你的美

    收藏

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1995929, encodeId=5a5419959296c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Feb 19 02:47:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787182, encodeId=119b1e8718253, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 13 15:47:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908199, encodeId=300b1908199d8, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Dec 22 16:47:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722429, encodeId=cc601e22429b6, content=<a href='/topic/show?id=7ff5549865a' target=_blank style='color:#2F92EE;'>#抑郁药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54986, encryptionId=7ff5549865a, topicName=抑郁药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fa33270286, createdName=wetgdt, createdTime=Tue Nov 22 05:47:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788170, encodeId=95851e881703b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Mar 20 15:47:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62872, encodeId=9e0a628e248, content=值得注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62873, encodeId=759d628e381, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62874, encodeId=fafc628e4dc, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60051, encodeId=dc576005141, content=恩,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:58:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59047, encodeId=e6b45904ebc, content=两面剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sun Jan 24 18:30:00 CST 2016, time=2016-01-24, status=1, ipAttribution=)]
    2016-02-02 收获你的美

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1995929, encodeId=5a5419959296c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Feb 19 02:47:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787182, encodeId=119b1e8718253, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 13 15:47:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908199, encodeId=300b1908199d8, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Dec 22 16:47:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722429, encodeId=cc601e22429b6, content=<a href='/topic/show?id=7ff5549865a' target=_blank style='color:#2F92EE;'>#抑郁药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54986, encryptionId=7ff5549865a, topicName=抑郁药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fa33270286, createdName=wetgdt, createdTime=Tue Nov 22 05:47:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788170, encodeId=95851e881703b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Mar 20 15:47:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62872, encodeId=9e0a628e248, content=值得注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62873, encodeId=759d628e381, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62874, encodeId=fafc628e4dc, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60051, encodeId=dc576005141, content=恩,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:58:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59047, encodeId=e6b45904ebc, content=两面剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sun Jan 24 18:30:00 CST 2016, time=2016-01-24, status=1, ipAttribution=)]
    2016-01-26 收获你的美

    恩,好

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1995929, encodeId=5a5419959296c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Feb 19 02:47:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787182, encodeId=119b1e8718253, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 13 15:47:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908199, encodeId=300b1908199d8, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Dec 22 16:47:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722429, encodeId=cc601e22429b6, content=<a href='/topic/show?id=7ff5549865a' target=_blank style='color:#2F92EE;'>#抑郁药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54986, encryptionId=7ff5549865a, topicName=抑郁药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fa33270286, createdName=wetgdt, createdTime=Tue Nov 22 05:47:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788170, encodeId=95851e881703b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Mar 20 15:47:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62872, encodeId=9e0a628e248, content=值得注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62873, encodeId=759d628e381, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62874, encodeId=fafc628e4dc, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Feb 02 18:10:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60051, encodeId=dc576005141, content=恩,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 20:58:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59047, encodeId=e6b45904ebc, content=两面剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sun Jan 24 18:30:00 CST 2016, time=2016-01-24, status=1, ipAttribution=)]
    2016-01-24 1de3b290m83(暂无匿称)

    两面剑

    0

相关资讯

Lancet Infect Dis:感染血吸虫的孕妇可放心使用吡喹酮治疗

尽管WHO建议,孕妇可以使用吡喹酮治疗,但许多国家继续拒绝治疗,并且等待着对照试验的安全性和有效性数据。这项研究的目的是评估治疗12-16周的妊娠期的孕妇血吸虫病是否可以改善孕产妇和新生儿的结局,并收集孕产妇和新生儿的安全性数据。这一阶段2,随机,双盲,安慰剂对照试验是在菲律宾莱特岛东北部血吸虫病流行地区的六市卫生中心的72个行政区域(村)完成的。那些感染了日本血吸虫但其他方面健康的孕妇(12-1

JAMA Pediatrics:孕期服用抗抑郁药易导致儿童自闭症

导致民众患自闭症谱系障碍(ASD)的风险因素十分复杂的,且十分庞大。这研究探究加拿大女性孕期服用抗抑郁药物对儿童患自闭症谱系障碍的影响。怀孕期间使用抗抑郁药对孕妇和孩子的影响仍然争论补休。医生也不清楚是否应该为孕妇开具抗抑郁药。若开具抗抑郁药物,可能胎儿有不利影响,如果不开具则对母亲有不利影响。在美国,有1/10的孕妇服用抗抑郁药物。面对孕妇普遍使用抗抑郁药物,研究人员认为他们有必要进行深入了解。

CMAJ:低风险妊娠人群在家中计划分娩的结局

100多年前,美国几乎所有的新生儿都出生在家中而非医院,但截至到1940年,只有44%的新生儿在家中降生,到1969年,在家中出生的新生儿仅占1%。现在,一项新的研究显示,孕妇在家中分娩并无太大的危害,也不会增加婴儿受伤的风险。加拿大安大略省麦克马斯特大学的Eileen Hutton博士领导进行了这项研究。研究结果发表在CMAJ。 根据CDC的数据显示,美国院外出生的婴儿比率由2011年的1.26

Stem Cells:日本研究人员发现孕期缺乏ω-3脂肪酸影响后代脑发育

日本研究人员在动物实验中发现,如果孕期大量摄取大豆和鸡蛋中含量丰富的ω-6脂肪酸,而缺乏鱼类、贝类中含量丰富的ω-3脂肪酸,会对胎儿的脑发育产生影响。大豆中的亚油酸和鸡蛋含有的花生四烯酸被划分为“ω-6脂肪酸”,而鱼类、贝类中含量丰富的二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)等则被分为“ω-3脂肪酸”。日本东北大学、理化学研究所和东京大学组成的一个研究小组给怀孕的雌实验鼠喂食含有过多“ω-

BJOG:孕妇吸烟,降低儿子的有氧适能!

孕妇吸烟毫无疑问会对母亲和婴儿造成伤害,它可以增加早产、出生缺陷和死胎等风险。尽管存在这些风险,许多孕妇仍旧继续吸烟。根据CDC从2011年美国24州的数据,研究人员发现约10%的女性在孕期后3个月内仍然吸烟。 芬兰奥卢大学的Maria Hagnäs博士和同事认为,孕妇吸烟可能会对男性后代的有氧适能带来不良后果。 “我们的研究进一步增加了母亲吸烟导致负面和长期影响的证据。”Hagnas博士说道。研

Baidu
map
Baidu
map
Baidu
map